The company is investing $1 billion in its Songdo Bio Campus in South Korea, with Plant 1 scheduled for completion this year and full-scale commercial production by 2027.
The company said the regulatory approval secures reliable and consistent supply of Contrave, more than doubling its capacity to produce the medication.
